Приказ основних података о документу

dc.creatorSavić, Snežana
dc.creatorTamburić, Slobodanka
dc.creatorSavić, Miroslav
dc.creatorCekić, Nebojša
dc.creatorMilić, J.
dc.creatorVuleta, G
dc.date.accessioned2019-09-02T10:59:21Z
dc.date.available2019-09-02T10:59:21Z
dc.date.issued2004
dc.identifier.issn0378-5173
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/528
dc.description.abstractIt is known that, depending on the concentration, treatment with urea could improve skin barrier function, despite its penetration-enhancing properties. This controversial skin effect of urea has been explored systematically in this study in terms of the effect of vehicle on the performance of urea. In the first part, a series of four semi-solid emulsions with 5% (w/w) urea, varying in the type of emulsion, nature of emulsifier and polarity of oil ingredients, have been evaluated with regard to their skin hydrating and transepidermal water loss (TEWL)-modifying properties. Placebo samples were tested alongside the urea-containing ones. Two best performing moisturisers from the above were chosen for the second part of the study, in which sodium lauryl sulphate (SLS)-irritated skin was treated with both placebo and urea-containing samples. In addition to TEWL and skin hydration level, the erythema index (EI) was measured before, during and after the treatment. The results have shown that barrier-improving and hydrating abilities of urea are bi-directional and dependent on both the type of vehicle used for its delivery and the state of skin.en
dc.publisherElsevier Science BV, Amsterdam
dc.rightsrestrictedAccess
dc.sourceInternational Journal of Pharmaceutics
dc.subjectureaen
dc.subjectmoisturiseren
dc.subjectskin hydrationen
dc.subjectTEWLen
dc.subjecterythema indexen
dc.subjectemulsionen
dc.titleVehicle-controlled effect of urea on normal and SLS-irritated skinen
dc.typearticle
dc.rights.licenseARR
dcterms.abstractМилић, Ј.; Савић, Мирослав; Савић, Снежана; Тамбурић, Слободанка; Вулета, Г; Цекић, Небојша;
dc.citation.volume271
dc.citation.issue1-2
dc.citation.spage269
dc.citation.epage280
dc.citation.other271(1-2): 269-280
dc.citation.rankM22
dc.identifier.wos000189248000028
dc.identifier.doi10.1016/j.ijpharm.2003.11.033
dc.identifier.pmid15129994
dc.identifier.scopus2-s2.0-1142279560
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу